{"id":"NCT04587453","sponsor":"LEO Pharma","briefTitle":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-27","primaryCompletion":"2021-07-06","completion":"2021-07-15","firstPosted":"2020-10-14","resultsPosted":"2022-09-22","lastUpdate":"2025-03-11"},"enrollment":106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Topical corticosteroids (TCS)","otherNames":[]}],"arms":[{"label":"Tralokinumab+TCS","type":"EXPERIMENTAL"},{"label":"Placebo+TCS","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective:\n\nTo evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, health-related quality of life, and health care resource utilisation compared with placebo in combination with TCS.\n\nTo assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 16 weeks.","primaryOutcome":{"measure":"Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Tralokinumab+TCS","deltaMin":17,"sd":null},{"arm":"Placebo+TCS","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":["40879371"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Acne","Nasopharyngitis","Injection site reaction","Pyrexia","Urticaria"]}}